Boehringer Ingelheim launches SCOVELLA® in Great Britain, the first approved therapy for insulin dysregulation in horses, a main cause of laminitis
Ingelheim, Germany, and Bracknell, United Kingdom SCOVELLA® is the first therapy specifically developed and approved for the treatment of hyperinsulinemia in insulin-dysregulated horses and ponies1, targeting the key underlying driver of laminitis.² Studies showed that SCOVELLA® rapidly and significantly reduces hyperinsulinemia with effects showing within days of starting treatment.4,6 Laminitis is one of the most […]
Financial Post
Published by CurrentWire · First coverage
Compiled by CurrentWire News Desk
Summary based on reporting from Financial Post.
Automated coverage analysis
Generated automatically from the coverage listed on this page. CurrentWire adds no editorial claims.
Coverage
1 publication is covering this story.
How CurrentWire compiled this story
Financial Post (financialpost.com), a Tier B publisher, filed this report on . CurrentWire published this page 26 minutes later, on .
Signal breakdown
CurrentWire ranked this story 58.7 of 100 in the snapshot this page was rendered from.
- Freshness
- 33.7 of 35
- Source authority
- 14 of 20
- Coverage breadth
- 4 of 20
- Geographic relevance
- 3.5 of 10
- Story prominence
- 3.5 of 10
- Velocity
- 0 of 5
Strongest signal: freshness, 33.7 of 35. How each signal is calculated.
Filed under Business · International · News. Topics extracted from this report, with other live CurrentWire stories mentioning each: Great Britain (none).
CurrentWire is a news discovery platform. This page summarizes and links to original reporting; full articles, imagery and copyright remain with the publishers listed above.